15 results on '"Alkhatib, Nimer"'
Search Results
2. Cost-effectiveness of Favipiravir in moderately to severely ill COVID-19 patients in the real-world setting of Saudi arabian pandemic referral hospitals
- Author
-
Alamer, Ahmad, primary, Almutairi, Abdulaali R., additional, Halloush, Shiraz, additional, Al-jedai, Ahmed, additional, Alrashed, Ahmed, additional, AlFaifi, Mashael, additional, Mohzari, Yahya, additional, Almutairi, Malak, additional, AlHassar, Fatimah, additional, Howaidi, Jude, additional, Almutairi, Wedad, additional, Abraham, Ivo, additional, and Alkhatib, Nimer, additional
- Published
- 2023
- Full Text
- View/download PDF
3. Cost-efficiency analysis and expanded treatment access modeling of conversion to rituximab biosimilars from reference rituximab in Jordan
- Author
-
Halawah, Hala H, Alkhatib, Nimer S, Almutairi, Abdulaali R, Saleh, Mohammad, Halloush, Shiraz S, Rashdan, Omar, Masadh, Lama, Abusara, Osama H, and Abraham, Ivo
- Abstract
To assess the cost-efficiency and expanded access of three rituximab biosimilars versus the reference rituximab from the perspective of the Jordanian national health payer. A 1-year cost-efficiency and expanded access model of conversion from reference rituximab (Mabthera) to the approved biosimilars (Truxima, Rixathon, and Tromax) to assess five metrics: total annual cost to treat a hypothetical patient; head-to-head cost comparison; changes in patients’ access to rituximab; number-needed-to-convert (NNC) to provide an additional 10 patients access to a rituximab treatment; and relative amount of Jordanian Dinar (JOD) spent on rituximab options. The model included rituximab doses at 100 mg/10 ml and 500 mg/50 ml and considered both cost-saving and cost-wastage scenarios. Costs of treatments were based on the fiscal year 2022 tender prices received by the Joint Procurement Department (JPD). Rixathon was associated with the lowest average annual cost per patient (JOD2,860) across all six indications among all rituximab comparators, followed by Truxima (JOD4,240), Tromax (JOD4,365) and reference Mabthera (JOD11,431). The highest percentage of patient access to rituximab treatment (321%) was achieved when switching patients from Mabthera to Rixathon in the RA and PV indications. At four patients, Rixathon was associated with the lowest NNC to provide an additional 10 patients access to rituximab treatment. For each JOD1 spent on Rixathon, an additional JOD3.21 must be spent on Mabthera, an additional JOD0.55 on Tromax, and an additional JOD0.53 on Truxima. Rituximab biosimilars were associated with cost savings in all approved indications in Jordan compared to reference rituximab. Rixathon was associated with the lowest annual cost, the highest percentage of expanded patient access for all six indications, and the lowest NNC providing 10 additional patients with access.
- Published
- 2023
- Full Text
- View/download PDF
4. Validation of the Arabic version of medication adherence report scale questionnaire and beliefs about medication -specific questionnaire: A factor analysis study
- Author
-
Al-Qerem, Walid, primary, Al Bawab, Abdel Qader, additional, Abusara, Osama, additional, Alkhatib, Nimer, additional, and Horne, Robert, additional
- Published
- 2022
- Full Text
- View/download PDF
5. Cost-efficiency analysis and expanded treatment access modeling of conversion to rituximab biosimilars from reference rituximab in Jordan.
- Author
-
Halawah, Hala H., Alkhatib, Nimer S., Almutairi, Abdulaali R., Saleh, Mohammad, Halloush, Shiraz S., Rashdan, Omar, Masadh, Lama, Abusara, Osama H., and Abraham, Ivo
- Subjects
RITUXIMAB ,MEDICAL care ,HEALTH outcome assessment ,MEDICAL technology ,MEDICAL economics - Abstract
To assess the cost-efficiency and expanded access of three rituximab biosimilars versus the reference rituximab from the perspective of the Jordanian national health payer. A 1-year cost-efficiency and expanded access model of conversion from reference rituximab (Mabthera) to the approved biosimilars (Truxima, Rixathon, and Tromax) to assess five metrics: total annual cost to treat a hypothetical patient; head-to-head cost comparison; changes in patients' access to rituximab; number-needed-to-convert (NNC) to provide an additional 10 patients access to a rituximab treatment; and relative amount of Jordanian Dinar (JOD) spent on rituximab options. The model included rituximab doses at 100 mg/10 ml and 500 mg/50 ml and considered both cost-saving and cost-wastage scenarios. Costs of treatments were based on the fiscal year 2022 tender prices received by the Joint Procurement Department (JPD). Rixathon was associated with the lowest average annual cost per patient (JOD2,860) across all six indications among all rituximab comparators, followed by Truxima (JOD4,240), Tromax (JOD4,365) and reference Mabthera (JOD11,431). The highest percentage of patient access to rituximab treatment (321%) was achieved when switching patients from Mabthera to Rixathon in the RA and PV indications. At four patients, Rixathon was associated with the lowest NNC to provide an additional 10 patients access to rituximab treatment. For each JOD1 spent on Rixathon, an additional JOD3.21 must be spent on Mabthera, an additional JOD0.55 on Tromax, and an additional JOD0.53 on Truxima. Rituximab biosimilars were associated with cost savings in all approved indications in Jordan compared to reference rituximab. Rixathon was associated with the lowest annual cost, the highest percentage of expanded patient access for all six indications, and the lowest NNC providing 10 additional patients with access. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Economic Analysis of glucagon like peptide-1 receptor agonists from the Saudi Arabia Payer Perspective
- Author
-
Alkhatib, Nimer S., primary, Almutairi, Abdulaali R., additional, Alkhezi, Omar S., additional, Alfayez, Osama M., additional, Al Yami, Majed S., additional, and Almohammed, Omar A., additional
- Published
- 2022
- Full Text
- View/download PDF
7. Meta-Analysis of Same-Day Pegfilgrastim Administration Stratified by Myelotoxic Febrile Neutropenia Risk and Tumor Type.
- Author
-
ALRAWASHDH, NEDA, McBRIDE, ALI, MOK OH, ALKHATIB, NIMER, LEE, CHRISTOPHER, MARTIN, JENNIFER, MacDONALD, KAREN, and ABRAHAM, IVO
- Published
- 2022
- Full Text
- View/download PDF
8. What Are the Factors Associated with Nonadherence to Medications in Patients with Chronic Diseases?
- Author
-
Al Bawab, Abdel Qader, primary, Al-Qerem, Walid, additional, Abusara, Osama, additional, Alkhatib, Nimer, additional, Mansour, Maha, additional, and Horne, Robert, additional
- Published
- 2021
- Full Text
- View/download PDF
9. Insulin injection technique in Western region of Algeria, Tlemcen
- Author
-
Boukli Hacene, Mohammed Nassim, primary, Saker, Meriem, additional, Youcef, Amina, additional, Koudri, Soumia Nassim, additional, Cheriet, Souad, additional, Merzouk, Hafida, additional, Lounici, Ali, additional, and Alkhatib, Nimer, additional
- Published
- 2020
- Full Text
- View/download PDF
10. Economic Evaluation for the US of Ibrutinib Versus Acalabrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma
- Author
-
Alrawashdh, Neda, primary, Alkhatib, Nimer, additional, McBride, Ali, additional, Persky, Daniel, additional, and Abraham, Ivo, additional
- Published
- 2018
- Full Text
- View/download PDF
11. Insulin injection technique in the western region of Algeria, Tlemcen.
- Author
-
Boukli Hacene, Mohammed Nassim, Saker, Meriem, Youcef, Amina, Koudri, Soumia, Cheriet, Souad, Merzouk, Hafida, Lounici, Ali, and Alkhatib, Nimer
- Abstract
Introduction: Algeria has more than 1.7 million diabetic patients on to whom a descriptive assessment particularly on the insulin usage behaviors has not yet been initiated, although is needed. This study aims to provide a descriptive analysis of how Algerian diabetic patients perceive and apply insulin injection techniques. Methods: using the "patient" questionnaire within the Injection Technique Questionnaire (ITQ) 2016 survey, this study assessed the insulin injection practices of 100 patients recruited over a seven-month period in western Algeria at the Tlemcen University Hospital Center. The results of this study are compared to those of the ITQ 2016 survey. Results: pens are the instruments of injection for 98% of Algerians who continue to use mostly long needles of 6- and 8-mm, although 4mm needles are the recommended safer option. Insulin analogues (fast and basal) are plebiscite. Arms and thighs are the preferred injection sites; the abdomen (the preferred site elsewhere) is neglected for reasons to be investigated. The correct re-suspension technique for cloudy insulin is unknown. Extensive pen needle re-use (10+ times) for over half of the patients exposes them to both higher intramuscular (IM) injection risk and lipohypertrophy (LH). Injection training is performed in Algeria by the diabetologist. Conclusion: this study describes for the first time Algerian patients' insulin injection technique. It highlights their skills and identifies many deficiencies which patients and professionals must correct given the issues in this area. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
12. Budget impact analysis of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma.
- Author
-
Abraham I, Calamia M, Alkhatib N, Pondel M, and MacDonald K
- Subjects
- Humans, Neoplasm Recurrence, Local drug therapy, Cost-Benefit Analysis, Antineoplastic Combined Chemotherapy Protocols economics, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Agents, Immunological economics, Antineoplastic Agents, Immunological therapeutic use, Immune Checkpoint Inhibitors therapeutic use, Immune Checkpoint Inhibitors economics, Deoxycytidine analogs & derivatives, Deoxycytidine therapeutic use, Deoxycytidine economics, Models, Econometric, Budgets, Gemcitabine, Neoplasm Metastasis, United States, Health Expenditures statistics & numerical data, Antibodies, Monoclonal, Humanized therapeutic use, Antibodies, Monoclonal, Humanized economics, Nasopharyngeal Carcinoma drug therapy, Nasopharyngeal Carcinoma economics, Nasopharyngeal Neoplasms drug therapy, Nasopharyngeal Neoplasms economics, Nasopharyngeal Neoplasms pathology
- Abstract
Aim: To estimate the budget impact of adding a toripalimab regimen as a treatment option to the existing pembrolizumab regimen, both including gemcitabine and cisplatin, in untreated recurrent/metastatic nasopharyngeal carcinoma (R/M NPC) using the published wholesale acquisition cost (WAC) and average sales price (ASP)., Methods: Budget impact analysis comparing a treatment mix "without" versus "with" the toripalimab regimen in the US eligible annual incident R/M NPC population, a 3-year time horizon, toripalimab/pembrolizumab market splits of 60/40 (Y1) and 80/20 (Y2/3), and medication adjustments for discontinuation or progression. Cost inputs included drugs, administration, and adverse event (AE) management. The models were replicated for a hypothetical 1-million-member health plan in which costs per-member-per-month (PMPM) and per-member-per-year (PMPY) were estimated. One-way (OWSA) and probabilistic sensitivity analyses (PSA) as well as scenario analyses were performed., Results: In the "without" scenario, the 3-year WAC-based costs for the pembrolizumab regimen total $1,449,695,333 ($1,305,632,448 for treatment and $144,062,885 for managing AEs). In the "with" scenario, total 3-year costs for pembrolizumab decline to $380,012,135 with toripalimab adding $885,505,900 ($779,206,567 for treatment and $106,299,333 for AE management). Annual net savings range from $46,526,152 in 2024 to $71,194,214 in 2026, for 3-year savings of $184,177,298. Associated net savings in a 1-million-member health plan are $543,068 over 3 years with savings of $0.045 PMPM and $0.543 PMPY. The ASP-based model shows similar patterns with 3-year net savings of $174,235,983 in the US incident population and savings of $0.043 PMPM and $0.514 PMPY in a 1-million-member health plan. The PSA support base case findings; OWSA and scenario analyses reveal how parameter variability impacts results., Conclusion: Savings between $174 million and $184 million can be achieved from treating 60% of R/M NPC patients in year 1 and 80% in years 2 and 3 with the toripalimab regimen over a similar pembrolizumab regimen.
- Published
- 2024
- Full Text
- View/download PDF
13. The economic impact of tobacco smoking and secondhand smoke exposure in Jordan: estimating the direct and indirect costs.
- Author
-
Alkhatib NS, Massad E, Rashdan O, Max W, Halloush S, Abumansour H, Alkhatib A, Karasneh RA, Al-Shatnawi S, Qirim T, Hawari F, and Alkhatib S
- Subjects
- Humans, Middle Aged, Adult, Jordan, Aged, Male, Female, Young Adult, Adolescent, Models, Econometric, Prevalence, Tobacco Smoke Pollution adverse effects, Tobacco Smoke Pollution economics, Cost of Illness, Health Expenditures statistics & numerical data, Tobacco Smoking economics, Tobacco Smoking adverse effects
- Abstract
Aim: To quantify the economic burden associated with tobacco smoking among smokers aged 30-69 years, and second-hand smokers (SHS) aged 15-69 years in Jordan., Materials and Methods: A prevalence-based analysis was conducted in alignment with the Economics of Tobacco Toolkit developed by the WHO. The time-horizon of the analysis was one year (2019). Direct and indirect costs were estimated using data from the 2019 Global Burden of Diseases study. The analysis targeted the Jordanian population of smokers aged 30-69 years, and SHS aged 15-69 years. Adjustments were applied for age, gender, and smoking-related diseases. Direct costs were estimated using the smoking-attributable fraction (SAF) and national health expenditures. Indirect costs were divided into morbidity and mortality components. A discount rate of 3.0% and an annual productivity growth rate of 1.0% were assumed in modelling future economic losses. A sensitivity analysis was conducted on the lower and upper estimates of data used in this study., Results: The cost of tobacco smoking and SHS exposure was estimated at US$2,108 million (95% confidence interval [CI] = US$2,003 million-US$2,245 million). This represents 4.7% (95%CI = 4.5%-5.0%) of national gross domestic product (GDP). Direct costs accounted for 3.1% of national GDP. Tobacco smoking accounted for 85.0% of total cost and SHS exposure accounted for 15.0% of total cost. Direct costs accounted for 67.0% of total cost, while indirect morbidity and mortality costs accounted for 9.0% and 24.0% of total cost, respectively. Non-communicable diseases accounted for 96.0% of total direct costs compared to communicable diseases (4.0% of total direct costs)., Conclusions: Smoking cessation interventions such as raising taxes on cigarettes, protecting people from tobacco smoke, warning labels, plain packaging, and bans on advertising, are crucial for controlling national expenditures for treating smoking-related diseases and for averting future economic losses.
- Published
- 2024
- Full Text
- View/download PDF
14. Meta-Analysis of Same-Day Pegfilgrastim Administration Stratified by Myelotoxic Febrile Neutropenia Risk and Tumor Type.
- Author
-
Alrawashdh N, McBride A, Oh M, Alkhatib N, Lee C, Martin J, MacDonald K, and Abraham I
- Abstract
Background: Pegfilgrastim is recommended to be administered at least 24 hours following the completion of chemotherapy, yet some clinicians use a same-day administration protocol. In this meta-analysis, we compared the incidence of chemotherapy-induced (febrile) neutropenia (CIN/FN) as well as CIN/FN-related chemotherapy disruptions in cancer patients provided with pegfilgrastim same-day vs. next-day., Methods: Six databases were searched for comparative studies of same-day vs. next-day pegfilgrastim administration. Fixed or random-effects meta-analyses were conducted to estimate pooled odds ratios (ORs) and 95% confidence intervals (CIs)., Results: Thirteen studies were included in this meta-analysis. The FN OR for same-day vs. next-day administration was 1.48 (95% CI = 1.06-2.08) across all cycles, attributable mainly to studies of high FN risk (OR = 2.46, 95% CI = 1.04-5.83) vs. intermediate FN risk regimens (OR = 1.41, 95% CI = 0.95-2.10), and breast cancer (OR = 3.15, 95% CI = 1.24-8.01) vs. non-Hodgkin lymphoma (NHL; OR = 1.48, 95% CI = 0.98-2.23) and gynecologic cancers (OR = 0.64, 95% CI = 0.11-3.85). Where available, ORs for first cycle of chemotherapy, grades 3 and/or 4 CIN, and chemotherapy dose delays or reductions were in line with these findings., Conclusion: In this independent study, same-day pegfilgrastim administration may or may not increase the likelihood of FN, grades 3 and/or 4 CIN, and chemotherapy dose reductions or delays; and this may be a function of the myelotoxicity of the regimens (elevated in high-risk but not intermediate-risk regimens) and tumor type (elevated in breast but not in NHL or gynecologic cancers). With due caution, same-day pegfilgrastim administration may be safe and beneficial in intermediate-risk regimens and selected tumor types., Competing Interests: Matrix45, LLC, which is co-owned by Dr. MacDonald and Dr. Abraham, received research support for an investigator-initiated study from Coherus Biosciences. The remaining authors have no conflicts of interest to disclose., (© 2022 Harborside™.)
- Published
- 2022
- Full Text
- View/download PDF
15. Insulin injection technique in the western region of Algeria, Tlemcen.
- Author
-
Hacene MNB, Saker M, Youcef A, Koudri S, Cheriet S, Merzouk H, Lounici A, and Alkhatib N
- Subjects
- Adult, Aged, Algeria epidemiology, Diabetes Mellitus drug therapy, Diabetes Mellitus epidemiology, Female, Health Knowledge, Attitudes, Practice, Humans, Injection Site Reaction epidemiology, Injection Site Reaction etiology, Injections, Intramuscular adverse effects, Injections, Subcutaneous adverse effects, Injections, Subcutaneous methods, Injections, Subcutaneous statistics & numerical data, Lipodystrophy chemically induced, Lipodystrophy epidemiology, Male, Middle Aged, Surveys and Questionnaires, Young Adult, Insulin administration & dosage, Needles adverse effects, Needles statistics & numerical data, Patient Preference statistics & numerical data
- Abstract
Introduction: Algeria has more than 1.7 million diabetic patients on to whom a descriptive assessment particularly on the insulin usage behaviors has not yet been initiated, although is needed. This study aims to provide a descriptive analysis of how Algerian diabetic patients perceive and apply insulin injection techniques., Methods: using the "patient" questionnaire within the Injection Technique Questionnaire (ITQ) 2016 survey, this study assessed the insulin injection practices of 100 patients recruited over a seven-month period in western Algeria at the Tlemcen University Hospital Center. The results of this study are compared to those of the ITQ 2016 survey., Results: pens are the instruments of injection for 98% of Algerians who continue to use mostly long needles of 6- and 8-mm, although 4mm needles are the recommended safer option. Insulin analogues (fast and basal) are plebiscite. Arms and thighs are the preferred injection sites; the abdomen (the preferred site elsewhere) is neglected for reasons to be investigated. The correct re-suspension technique for cloudy insulin is unknown. Extensive pen needle re-use (10+ times) for over half of the patients exposes them to both higher intramuscular (IM) injection risk and lipohypertrophy (LH). Injection training is performed in Algeria by the diabetologist., Conclusion: this study describes for the first time Algerian patients´ insulin injection technique. It highlights their skills and identifies many deficiencies which patients and professionals must correct given the issues in this area., Competing Interests: The authors declare no competing interests., (Copyright: Mohammed Nassim Boukli Hacene et al.)
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.